{"id":24354,"date":"2022-11-15T13:04:00","date_gmt":"2022-11-15T05:04:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24354"},"modified":"2025-01-31T13:15:43","modified_gmt":"2025-01-31T05:15:43","slug":"peru-approves-bmss-reblozyl-and-beigenes-brukinsa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24354","title":{"rendered":"Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa"},"content":{"rendered":"\n

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE: BMY<\/a>) erythropoietic aid Reblozyl (luspatercept) and BeiGene’s (NASDAQ: BGNE; HKG: 6160<\/a>; SHA: 688235<\/a>) Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech<\/a> analysis. The approvals mark significant milestones for both drugs in the Latin American market.<\/p>\n\n\n\n

Drug Profiles and Indications<\/strong>
Reblozyl is indicated for the treatment of anemia associated with beta thalassemia, myelodysplastic syndromes with ring sideroblasts (MDS-RS), and myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T). The drug is a recombinant fusion protein that acts as an erythroid maturation agent by binding to several members of the transforming growth factor-\u03b2 (TGF-\u03b2) superfamily of ligands, which is upstream of the Smad2\/3 pathway that displays elevated signaling in beta thalassemia and MDS.<\/p>\n\n\n\n

Brukinsa, developed by BeiGene, is a BTK inhibitor that inhibits the proliferation and survival of malignant B lymphocytes by covalently binding to the active site of BTK, an enzyme crucial for B lymphocyte proliferation, trafficking, chemotaxis, and adhesion. Last month, BeiGene announced several Latin American approvals for Brukinsa in mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Waldenstr\u00f6m’s macroglobulinemia (WM).<\/p>\n\n\n\n

Market and Competitive Landscape<\/strong>
Fineline Info & Tech<\/a> analysis indicates that this is the third regulatory approval for BMS’s Reblozyl in Latin America, following approvals in Brazil and Uruguay. Meanwhile, BeiGene’s Brukinsa will enter Peru’s competitive BTK inhibitor market, where it will compete with Johnson & Johnson’s (J&J; NYSE: JNJ<\/a>) Imbruvica (ibrutinib), AstraZeneca’s (AZ, NASDAQ: AZN<\/a>) Calquence (acalabrutinib), and several ibrutinib generics. Brukinsa is already available in Argentina, Mexico, Brazil, Chile, Ecuador, El Salvador, Paraguay, and Uruguay.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,770,185,2092,429,428,847,150,149,871,849,858,848],"class_list":["post-24354","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-az","tag-beigene","tag-beone-medicines","tag-bms","tag-bristol-myers-squibb","tag-hkg-6160","tag-jj","tag-johnson-johnson","tag-nasdaq-azn","tag-nyse-bmy","tag-nyse-jnj","tag-sha-688235"],"yoast_head":"\nPeru Approves BMS's Reblozyl and BeiGene's Brukinsa - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Peru's General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb's (BMS; NYSE: BMY) erythropoietic aid Reblozyl (luspatercept) and BeiGene's (NASDAQ: BGNE; HKG: 6160; SHA: 688235) Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech analysis. The approvals mark significant milestones for both drugs in the Latin American market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24354\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peru Approves BMS's Reblozyl and BeiGene's Brukinsa\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24354\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T05:04:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T05:15:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa\",\"datePublished\":\"2022-11-15T05:04:00+00:00\",\"dateModified\":\"2025-01-31T05:15:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"BeiGene\",\"BeOne Medicines\",\"BMS\",\"Bristol-Myers Squibb\",\"HKG: 6160\",\"J&J\",\"Johnson & Johnson\",\"NASDAQ: AZN\",\"NYSE: BMY\",\"NYSE: JNJ\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24354#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24354\",\"name\":\"Peru Approves BMS's Reblozyl and BeiGene's Brukinsa - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-15T05:04:00+00:00\",\"dateModified\":\"2025-01-31T05:15:43+00:00\",\"description\":\"Peru's General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb's (BMS; NYSE: BMY) erythropoietic aid Reblozyl (luspatercept) and BeiGene's (NASDAQ: BGNE; HKG: 6160; SHA: 688235) Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech analysis. The approvals mark significant milestones for both drugs in the Latin American market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24354\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24354#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peru Approves BMS's Reblozyl and BeiGene's Brukinsa - Insight, China's Pharmaceutical Industry","description":"Peru's General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb's (BMS; NYSE: BMY) erythropoietic aid Reblozyl (luspatercept) and BeiGene's (NASDAQ: BGNE; HKG: 6160; SHA: 688235) Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech analysis. The approvals mark significant milestones for both drugs in the Latin American market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24354","og_locale":"en_US","og_type":"article","og_title":"Peru Approves BMS's Reblozyl and BeiGene's Brukinsa","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24354","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-15T05:04:00+00:00","article_modified_time":"2025-01-31T05:15:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24354#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24354"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa","datePublished":"2022-11-15T05:04:00+00:00","dateModified":"2025-01-31T05:15:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24354"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","BeiGene","BeOne Medicines","BMS","Bristol-Myers Squibb","HKG: 6160","J&J","Johnson & Johnson","NASDAQ: AZN","NYSE: BMY","NYSE: JNJ","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24354#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24354","url":"https:\/\/flcube.com\/?p=24354","name":"Peru Approves BMS's Reblozyl and BeiGene's Brukinsa - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-15T05:04:00+00:00","dateModified":"2025-01-31T05:15:43+00:00","description":"Peru's General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb's (BMS; NYSE: BMY) erythropoietic aid Reblozyl (luspatercept) and BeiGene's (NASDAQ: BGNE; HKG: 6160; SHA: 688235) Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), according to Fineline Info & Tech analysis. The approvals mark significant milestones for both drugs in the Latin American market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24354#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24354"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24354#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24354"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24354\/revisions"}],"predecessor-version":[{"id":24355,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24354\/revisions\/24355"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}